Day 3: Thursday, March 19th, 2026Thursday, 19 March 2026 - EST/EDT (Eastern Daylight, GMT-4)

Navigate the complex decisions around distribution models to ensure patients can access therapy through their preferred channels. This comprehensive session addresses key distribution considerations across multiple scenarios.

• Evaluate buy-and-bill versus specialty pharmacy models based on product and market needs

• Implement strategies to capture and redirect prescriptions that go to out-of-network pharmacies

• Navigate the transition from specialty to retail distribution channels when appropriate

• Design distribution networks that balance access, economics, and control

During this session, assess the newest Direct to Consumer Models to understand which companies, and which products, are choosing this route and why. Evaluate the implications for patients and intermediaries and determine what is real vs what is smoke and mirrors.

In today’s competitive and regulated pharmaceutical landscape, patient support programs — from copay assistance and affordability hubs to adherence services — play a pivotal role in driving access and improving outcomes. However, these same programs directly influence the financial performance of brands by affecting net revenue realization and GTN forecasting. This session will explore how finance, commercial, and access teams can collaborate to align hub program design with Gross-to-Net strategy.

• Understand how patient support elements like copay assistance, free drug programs, bridge therapy, and foundations impact accruals and GTN forecasting

• Explore strategies to optimize GTN without limiting patient access or jeopardizing hub engagement metrics

• Leverage claims-level data and hub insights to improve visibility into real-time GTN impacts and detect fraud or misuse

• Navigate emerging risks related to accumulators, maximizers, and payer pushback against manufacturer assistance

• Identify operational best practices for embedding hub-related GTN logic into forecasting, accrual validation, and revenue recognition workflows

This session will examine the evolving regulatory environment impacting patient assistance programs and explore the operational implications of emerging alternative distribution models. Attendees will gain insights into the dramatic rise of direct-to-consumer, direct-to-employer and cash buy programs, including recent developments like TrumpRx, and understand how these shifts are fundamentally changing patient access strategies. The discussion will focus on practical implementation considerations and compliance requirements that hub operations must navigate in this rapidly changing landscape.

In this closing session, come back to the core of our conference with a focus on the patient journey, patient experience and patient outcomes. Here and see the direct impact of what we have learned and discussed over the course of the conference and be inspired for the year ahead.